ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 128 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q3 2020. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $797,827 | +81.7% | 32,765 | +152.1% | 0.43% | +77.5% |
| Q1 2024 | $438,976 | -48.3% | 12,999 | -51.7% | 0.24% | -52.8% |
| Q4 2023 | $848,724 | +27.1% | 26,918 | +3.0% | 0.52% | +85.3% |
| Q3 2023 | $667,621 | +9.4% | 26,130 | +22.8% | 0.28% | +2.6% |
| Q2 2023 | $610,138 | -20.9% | 21,274 | -33.9% | 0.27% | -26.7% |
| Q1 2023 | $771,091 | +117.8% | 32,169 | +43.0% | 0.37% | +42.1% |
| Q2 2022 | $354,000 | +40.5% | 22,499 | +326.1% | 0.26% | +31.2% |
| Q3 2021 | $252,000 | +16.1% | 5,280 | -17.7% | 0.20% | +26.8% |
| Q2 2021 | $217,000 | -50.7% | 6,417 | -37.4% | 0.16% | -52.1% |
| Q3 2020 | $440,000 | -17.9% | 10,248 | -10.7% | 0.33% | -20.2% |
| Q2 2020 | $536,000 | -22.7% | 11,478 | -77.5% | 0.41% | -51.1% |
| Q1 2020 | $693,000 | +22.7% | 51,021 | -1.8% | 0.84% | +103.4% |
| Q4 2019 | $565,000 | +43.0% | 51,982 | +35.2% | 0.41% | +26.7% |
| Q3 2019 | $395,000 | +9.4% | 38,461 | +0.7% | 0.33% | +42.4% |
| Q2 2019 | $361,000 | – | 38,207 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Portolan Capital Management | 484,907 | $11,807,485 | 0.97% |
| Nikko Asset Management Americas, Inc. | 1,563,065 | $37,966,849 | 0.44% |
| Diametric Capital, LP | 32,765 | $797,827 | 0.43% |
| ARK Investment Management | 1,964,964 | $47,846,871 | 0.42% |
| SummerHaven Investment Management, LLC | 23,400 | $569,790 | 0.38% |
| Quantedge Capital Pte Ltd | 40,800 | $993,480 | 0.36% |
| Granahan Investment Management | 344,549 | $8,389,768 | 0.34% |
| FEDERATED HERMES, INC. | 4,694,060 | $114,300,361 | 0.27% |
| Belmont Capital, LLC | 40,000 | $974,000 | 0.18% |
| Woodline Partners LP | 754,023 | $18,360,460 | 0.18% |